Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vizokul is an over-the-counter (OTC) ophthalmic solution marketed by Akrovis Pharmaceuticals, a generic and consumer healthcare company based in India. The product is a combination formulation typically containing the decongestants naphazoline hydrochloride and phenylephrine hydrochloride, along with cooling agents such as camphor and menthol. It is indicated for the temporary relief of eye redness, minor irritation, and congestion caused by environmental factors like dust, smoke, or wind. Naphazoline and phenylephrine act as sympathomimetic amines that stimulate alpha-adrenergic receptors, leading to vasoconstriction of the conjunctival blood vessels and a reduction in ocular redness. Menthol and camphor provide a cooling, soothing sensation on the ocular surface.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vizokul.